Blue Cell Therapeutics is a biotechnology company founded in Copenhagen that focuses on revolutionizing the treatment of erectile dysfunction using specialized cell therapy.
Subscribe to see Blue Cell Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Blue Cell Therapeutics is a biotechnology company headquartered in Denmark. Its most recent funding round, Angel, closed in October 2024. Xcout tracks 6 named people at Blue Cell Therapeutics, including Søren P. Sheikh (Chief Executive Officer).
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Angel | Undisclosed | 1 named | |
| Grant | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Blue Cell Therapeutics's closest competitors — see the full list of competitors and alternatives →
BlueRock Therapeutics is a clinical-stage cell therapy company headquartered in Cambridge, Massachusetts, focused on developing engineered cellular medicines for degenerative conditions.
BlueWhale Bio, Inc. is dedicated to accelerating the growth and adoption of cell-based therapies by pioneering next-generation cell therapy manufacturing.
BLOOCELL is a biotechnology company specializing in artificial tissue technology, focusing on advanced bone and cartilage repair matrix solutions.
Innovacell Inc. is a biotech company that develops, manufactures, and sells cell therapy and regenerative medicine products aimed at treating fecal and urinary incontinence. The company's pipeline includes treatments for urgent fecal incontinence, leaky fecal incontinence, and stress urinary incontinence using the patient's own cells.
Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.
Ferring Ventures is a research company based in Kuopio, Finland, specializing in the translational field of cell therapy. The organization focuses on the discovery, establishment, and development of Advanced Therapy Medicinal Products (ATMPs) through Phase I and IIa clinical trials.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.